<div id="readability-page-1"><div>By Colin Kellaher A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit its goal in a second late-stage study in patients with a hard-to-treat form of bladder cancer. The companies on Wednesday said Merck's Keytruda coupled with Padcev from Pfizer and Astellas showed significantly improved survival for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy. The study met its primary endpoint, demonstrating clinically meaningful and statistically significant improvements in event-free survival, as well as in overall survival, a key secondary endpoint, the companies said. Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, said they plan to discuss the study results with global health authorities for potential regulatory filings. Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Padcev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late 2023. The combination is already approved for the treatment of adults with locally advanced or metastatic urothelial cancer in the U.S., the European Union, Japan and several other countries around the world. Write to Colin Kellaher at colin.kellaher@wsj.com (END) Dow Jones Newswires12-17-25 0753ET</div></div>

安斯泰萊制藥(ADR)

輝瑞

默克

默克、輝瑞和安斯泰萊製藥的藥物組合 Keytruda 和 Padcev 在第二階段 III 研究中成功治療肌肉侵襲性膀胱癌。研究顯示生存率顯著改善，達到了主要和次要終點。這些公司計劃與衞生當局討論結果，以進行監管申請。該組合已在全球範圍內獲得對晚期尿路上皮癌治療的批准

Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study

- 默克、輝瑞和阿斯利康的聯合癌症藥物在晚期膀胱癌研究中成功。  
- 研究顯示此組合顯著改善肌肉侵襲性膀胱癌患者的生存率。  
- 公司計劃與全球衞生機構討論研究結果以擬定監管申請。

默克、輝瑞和安斯泰萊製藥的藥物組合在第二個三期膀胱癌研究中取得成功